US 11,980,592 B2
Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
Andrea Small-Howard, Norwalk, CA (US); and Helen Turner, Honolulu, HI (US)
Assigned to GBS Global Biopharma, Inc., Ottawa (CA)
Filed by GBS GLOBAL BIOPHARMA, INC., Ottawa (CA)
Filed on Apr. 9, 2020, as Appl. No. 16/844,713.
Application 16/844,713 is a continuation of application No. 15/729,565, filed on Oct. 10, 2017, granted, now 10,653,640.
Claims priority of provisional application 62/406,764, filed on Oct. 11, 2016.
Prior Publication US 2020/0338017 A1, Oct. 29, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/05 (2006.01); A61K 9/00 (2006.01); A61K 31/015 (2006.01); A61K 31/045 (2006.01); A61K 31/352 (2006.01); A61K 36/185 (2006.01); A61K 45/06 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/05 (2013.01) [A61K 9/0073 (2013.01); A61K 9/0078 (2013.01); A61K 31/015 (2013.01); A61K 31/045 (2013.01); A61K 31/352 (2013.01); A61K 36/185 (2013.01); A61K 45/06 (2013.01); A61P 25/28 (2018.01)] 16 Claims
 
1. A method of treating Parkinson's disease, the method comprising:
administering an effective amount of a pharmaceutical composition to a patient having Parkinson's disease, wherein the pharmaceutical composition comprises chemically synthesized:
(i) cannabidiol (CBD) and
(ii) a minor cannabinoid selected from the group consisting of cannabidivarin (CBDV) and cannabichromene (CBC).